VIP and diffuse large B-cell lymphoma: The use of antagonists against PI3Kδ and the vasoactive intestinal peptide (VIP) during ex vivo expansion of DLBCL patient T cells led to the inhibition of the terminal T cell differentiation, reduced PD-1 expression, and improved T cell persistence in immune-deficient mice [130].